Biogen announced a $2 billion investment to expand its manufacturing capabilities across multiple modalities at its Research Triangle Park campuses. The expansion strengthens antisense oligonucleotide (ASO) production and multi-platform fill-finish operations, incorporating advanced automation and AI technologies. This investment supplements prior spending of approximately $10 billion in the region and aims to support Biogen's late-stage pipeline and enhance resilient patient supply.